Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

  • Showing results for a modified search because your search retrieved no results.
1.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ.

J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8.

PMID:
15007088
2.

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV.

J Clin Pharmacol. 2007 Jan;47(1):78-86.

PMID:
17192505
3.

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.

Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM.

J Clin Oncol. 2007 Jun 20;25(18):2594-600.

PMID:
17577039
4.

Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.

Lu YY, Huang XE, Wu XY, Cao J, Liu J, Wang L, Xiang J.

Asian Pac J Cancer Prev. 2014;15(7):3335-41.

5.

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.

Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y.

Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16.

6.

UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.

Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M.

Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27.

7.

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ.

J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.

8.

Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.

Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K, Shimokata K, Hasegawa Y.

Pharmacogenet Genomics. 2005 Jan;15(1):35-41.

PMID:
15864124
9.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.

Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM.

Cancer Chemother Pharmacol. 2017 Jul;80(1):135-149. doi: 10.1007/s00280-017-3344-3. Epub 2017 Jun 5. Review.

PMID:
28585035
10.

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y.

Cancer Sci. 2006 Nov;97(11):1255-9. Epub 2006 Sep 12.

11.

Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.

Zhang A, Xing Q, Qin S, Du J, Wang L, Yu L, Li X, Xu L, Xu M, Feng G, He L.

Pharmacogenomics J. 2007 Oct;7(5):333-8. Epub 2006 Oct 24.

PMID:
17060921
12.

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.

Innocenti F, Grimsley C, Das S, Ramírez J, Cheng C, Kuttab-Boulos H, Ratain MJ, Di Rienzo A.

Pharmacogenetics. 2002 Dec;12(9):725-33. Erratum in: Pharmacogenetics. 2003 Mar;13(3):183.

PMID:
12464801
13.

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y.

Cancer Res. 2000 Dec 15;60(24):6921-6.

14.
15.

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer. 2008 May 1;112(9):1932-40. doi: 10.1002/cncr.23370.

16.

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L.

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.

PMID:
23686699
17.

[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].

Li H, Huang H, Liu JH.

Zhonghua Fu Chan Ke Za Zhi. 2011 Dec;46(12):888-91. Chinese.

PMID:
22333276
18.

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ.

Pharmacogenomics J. 2002;2(1):43-7.

PMID:
11990381
19.

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K.

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z. Epub 2009 Apr 24.

PMID:
19390945
20.

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.

Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ.

Clin Pharmacol Ther. 1999 May;65(5):576-82.

PMID:
10340924

Supplemental Content

Support Center